144 related articles for article (PubMed ID: 23731704)
41. Effects of anti-Müllerian hormone and follicle stimulating hormone levels on in vitro fertilization pregnancy rate.
Chen YP; Wu WH; Wu HM; Chen CK; Wang HS; Huang HY
Taiwan J Obstet Gynecol; 2014 Sep; 53(3):313-6. PubMed ID: 25286783
[TBL] [Abstract][Full Text] [Related]
42. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
[TBL] [Abstract][Full Text] [Related]
43. CGG repeat sizing in the FMR1 gene in Indian women with premature ovarian failure.
Chatterjee S; Maitra A; Kadam S; Patel Z; Gokral J; Meherji P
Reprod Biomed Online; 2009 Aug; 19(2):281-6. PubMed ID: 19712568
[TBL] [Abstract][Full Text] [Related]
44. Indicators of anxiety and depression in women with the fragile X premutation: assessment of a clinical sample.
Lachiewicz A; Dawson D; Spiridigliozzi G; Cuccaro M; Lachiewicz M; McConkie-Rosell A
J Intellect Disabil Res; 2010 Jul; 54(7):597-610. PubMed ID: 20629912
[TBL] [Abstract][Full Text] [Related]
45. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation.
Bodega B; Bione S; Dalprà L; Toniolo D; Ornaghi F; Vegetti W; Ginelli E; Marozzi A
Hum Reprod; 2006 Apr; 21(4):952-7. PubMed ID: 16361284
[TBL] [Abstract][Full Text] [Related]
46. AGG interspersion analysis of the FMR1 CGG repeats in mental retardation of unspecific cause.
Poon PM; Chen QL; Zhong N; Lam ST; Lai KY; Wong CK; Pang CP
Clin Biochem; 2006 Mar; 39(3):244-8. PubMed ID: 16337617
[TBL] [Abstract][Full Text] [Related]
47. Premutations of FMR1 CGG repeats are not related to idiopathic premature ovarian failure in Iranian patients: A case control study.
Asadi R; Omrani MD; Ghaedi H; Mirfakhraie R; Azargashb E; Habibi M; Pouresmaeili F
Gene; 2018 Nov; 676():189-194. PubMed ID: 30030199
[TBL] [Abstract][Full Text] [Related]
48. Analysis of CGG repeats in FMR1 in Chinese women with idiopathic premature ovarian failure.
Ye Y; Lan X; Cong J; Li N; Wu Y; Zhang M; Liu J; Cui Y; Wu BL; An Y; Wu J
Reprod Biomed Online; 2014 Sep; 29(3):382-7. PubMed ID: 24912415
[TBL] [Abstract][Full Text] [Related]
49. [Low circulating anti-Müllerian hormone and normal follicle stimulating hormone levels: which prognosis in an IVF program?].
Grzegorczyk-Martin V; Khrouf M; Bringer-Deutsch S; Mayenga JM; Kulski O; Cohen-Bacrie P; Benaim JL; Belaisch-Allart J
Gynecol Obstet Fertil; 2012; 40(7-8):411-8. PubMed ID: 22521986
[TBL] [Abstract][Full Text] [Related]
50. Is the immunological noise of abnormal autoimmunity an independent risk factor for premature ovarian aging?
Gleicher N; Weghofer A; Oktay K; Barad DH
Menopause; 2009; 16(4):760-4. PubMed ID: 19197218
[TBL] [Abstract][Full Text] [Related]
51. Menstrual cycle length in relation to antimüllerian hormone and follicle-stimulating hormone.
Rashidi BH; Abediasl Z; Tehraninejad ES; Shariat M; Mahdavi A
J Reprod Med; 2009 May; 54(5):315-8. PubMed ID: 19517697
[TBL] [Abstract][Full Text] [Related]
52. Genetic analysis of FMR1 repeat expansion in essential tremor.
Clark LN; Ye X; Liu X; Louis ED
Neurosci Lett; 2015 Apr; 593():114-7. PubMed ID: 25796179
[TBL] [Abstract][Full Text] [Related]
53. FMR1 premutation: not only important in premature ovarian failure but also in diminished ovarian reserve.
Eslami A; Farahmand K; Totonchi M; Madani T; Asadpour U; Zari Moradi S; Gourabi H; Mohseni-Meybodi A
Hum Fertil (Camb); 2017 Jun; 20(2):120-125. PubMed ID: 27876427
[TBL] [Abstract][Full Text] [Related]
54. Correlation of antimüllerian hormone and baseline follicle-stimulating hormone levels.
Singer T; Barad DH; Weghofer A; Gleicher N
Fertil Steril; 2009 Jun; 91(6):2616-9. PubMed ID: 18555223
[TBL] [Abstract][Full Text] [Related]
55. FMR1 and the continuum of primary ovarian insufficiency.
Sullivan SD; Welt C; Sherman S
Semin Reprod Med; 2011 Jul; 29(4):299-307. PubMed ID: 21969264
[TBL] [Abstract][Full Text] [Related]
56. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
57. Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients.
Elgindy EA; El-Haieg DO; El-Sebaey A
Fertil Steril; 2008 Jun; 89(6):1670-6. PubMed ID: 17658520
[TBL] [Abstract][Full Text] [Related]
58. Pathological Effects of the FMR1 CGG-Repeat Polymorphism (5-55 Repeat Numbers): Systematic Review and Meta-Analysis.
Yang W; Fan C; Chen L; Cui Z; Bai Y; Lan F
Tohoku J Exp Med; 2016 May; 239(1):57-66. PubMed ID: 27193037
[TBL] [Abstract][Full Text] [Related]
59. The significance of FMR1 CGG repeats in Chinese women with premature ovarian insufficiency and diminished ovarian reserve.
Tang R; Yu Q
Reprod Biol Endocrinol; 2020 Aug; 18(1):82. PubMed ID: 32787884
[TBL] [Abstract][Full Text] [Related]
60. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
